Dr. Ronald T. Ackerman SR., MD
OB-GYN (Obstetrics & Gynecology) (Gynecology Physician)
- Medicare participating
At a glance
- Years since graduation
- 48
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 19
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecology Physician primary
FL license ME0043294
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Where they work
Medical groups
- Raulerson Gyn LLC (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 19
- Services billed
- 47
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 28 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Progesterone (progesterone, micronized) Other prescribers in West PAlm Beach, FL | 15 |
| Nystatin-Triamcinolone (nystatin/triamcinolone acet) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 10 payments worth $6,357 in total to this clinician.
| Eli Lilly and Company | $4,412 |
|---|---|
| Genbiopro, Inc. | $1,860 |
| Astellas Pharma US Inc | $48.31 |
| Hologic Sales and Service, LLC | $18.51 |
| Millicent US Inc | $17.95 |
| Consulting Fee | $5,235 |
|---|---|
| Travel and Lodging | $860 |
| Food and Beverage | $262 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company Oct 30, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,375 |
| Genbiopro, Inc. Dec 31, 2025 | Consulting Fee | $1,860 |
| Eli Lilly and Company Sep 19, 2025 | Travel and Lodging travel to INDIANAPOLIS, FL · in-kind | $445 |
| Eli Lilly and Company Sep 19, 2025 | Travel and Lodging travel to INDIANAPOLIS, FL · in-kind | $334 |
| Eli Lilly and Company Nov 13, 2025 | Travel and Lodging travel to INDIANAPOLIS, IN | $81.54 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $5,055 in research payments for these studies, mostly to the institutions running them.
- Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females
Exeltis, USA Inc. · Completed · NCT05461573 - A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
Sumitomo Pharma America, Inc. · Recruiting · NCT05862272 - A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.